Bayer (Canada)

BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

Alexander G.G. Turpie, W. D. Fisher, Kenneth A. Bauer et al. · Journal of Thrombosis and Haemostasis · 2005 · 301 citations · Full text

Total Knee Replacement, Thrombosis, Venous Disease +9

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

Malcolm J. Moore, Holger W. Hirte, Lillian L. Siu et al. · Annals of Oncology · 2005 · 301 citations

Medicine, Pharmacology, Days On/7 Days +6

Central venous line–related thrombosis in children: association with central venous line location and insertion technique

Christoph Male, Peter Chait, Maureen Andrew et al. · Blood · 2003 · 240 citations · Full text

Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection

Kenneth R. Gundle, Lisa Kafchinski, Sanjay Gupta et al. · Journal of Clinical Oncology · 2018 · 213 citations

Barley: Production, Improvement, and Uses

A. Goyal, Mukhtar Ahmed · Crop Science · 2012 · 197 citations

Sustainable Agriculture, Agricultural Economics, Plant Production +3